# US 2013/0158023 A1 · Identification of gene expression as a predictive biomarker for lkb1 status

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158023 A1
- Document ID: US20130158023A1
- Status: Published application
- Kind: A1
- Application number: 13/701,224
- Filed: 2012-08-02
- Published: 2013-06-20
- Earliest claimed: 2011-08-03
- Assignees: Signal Pharmaceuticals, LLC
- Inventors: Yuhong L. Ning; Weiming Xu; Rajesh Chopra; Peter Worland; Shuichan Xu
- Web page: https://patentgrep.com/patent/US20130158023A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods for predicting the LKB1 status of a patient or a biological sample, comprising the measurement of particular gene expression levels relative to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation. Further provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by particular gene expression levels.

## Claims

### Claim 1

A method for predicting LKB1 gene or protein loss or mutation in a patient's cancer, comprising:
a) obtaining a biological test sample from the patient's cancer;
b) obtaining the gene expression level of one or more genes selected from Table 1 in said biological sample;
c) comparing said gene expression level to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation, and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation;
wherein the gene expression level of the biological test sample characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation, indicates an increased likelihood of an LKB1 gene or protein loss or mutation in the patient's cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gene expression level of the biological test sample is obtained using gene mRNA measurement.

### Claim 3 (depends on 1)

The method of claim 1, wherein the gene expression level of the biological test sample is obtained using RT-PCR or Affymetrix HGU133plus2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the comparison of gene expression levels is performed using PAMR.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung carcinoma or cervical cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the gene expression level of the biological test sample is characterized by an upregulation of one or more genes in Table 1 as having a negative Fold Change value.

### Claim 7 (depends on 1)

The method of claim 1, wherein the gene expression level of the biological test sample is characterized by a downregulation of one or more genes in Table 1 as having a positive Fold Change value.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene expression level of the biological test sample is characterized by upregulation of one or more of the following genes: scavenger receptor class A, member 5 (putative); fibrinogen gamma chain; fibrinogen alpha chain; insulin-like 4 (placenta); organic solute transporter beta; phosphodiesterase 1A, calmodulin-dependent; carbamoyl-phosphate synthetase 1, mitochondrial; frizzled homolog 10 (Drosophila); mucin SAC, oligomeric mucus/gel-forming; trefoil factor 1; transient receptor potential cation channel, subfamily C, member 6; interleukin 1 receptor, type II; fibrinogen beta chain; chromosome 12 open reading frame 39; hypothetical gene supported by AK090616; R-spondin 3 homolog (Xenopus laevis); and interleukin 1 receptor, type II.

### Claim 9 (depends on 1)

The method of claim 1, wherein the gene expression level is characterized by downregulation of one or more of the following genes: chitinase 3-like 1 (cartilage glycoprotein-39); odz, odd Oz/ten-m homolog 2 (Drosophila); chemokine (C—C motif) ligand 5; bone morphogenetic protein 4; calcyphosine; Uncharacterized protein LOC100131897; and CD74 molecule, major histocompatibility complex, class II invariant chain.

### Claim 10

A method for treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, comprising administering an effective amount of a TOR kinase inhibitor to a patient having non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, wherein the gene expression level of a biological test sample from said patient is characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is obtained using gene mRNA measurement.

### Claim 12 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is obtained using RT-PCR or Affymetrix HGU133plus2.

### Claim 13 (depends on 10)

The method of claim 10, wherein the comparison of expression levels is performed using PAMR.

### Claim 14 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is characterized by an upregulation of one or more genes indicated in Table 1 as having a negative Fold Change value.

### Claim 15 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is characterized by a downregulation of one or more genes in Table 1 as having a positive Fold Change value.

### Claim 16 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is characterized by upregulation of one or more of the following genes: scavenger receptor class A, member 5 (putative); fibrinogen gamma chain; fibrinogen alpha chain; insulin-like 4 (placenta); organic solute transporter beta; phosphodiesterase 1A, calmodulin-dependent; carbamoyl-phosphate synthetase 1, mitochondrial; frizzled homolog 10 (Drosophila); mucin SAC, oligomeric mucus/gel-forming; trefoil factor 1; transient receptor potential cation channel, subfamily C, member 6; interleukin 1 receptor, type II; fibrinogen beta chain; chromosome 12 open reading frame 39; hypothetical gene supported by AK090616; R-spondin 3 homolog (Xenopus laevis); and interleukin 1 receptor, type II.

### Claim 17 (depends on 10)

The method of claim 10, wherein the gene expression level of the biological test sample is characterized by downregulation of one or more of the following genes: chitinase 3-like 1 (cartilage glycoprotein-39); odz, odd Oz/ten-m homolog 2 (Drosophila); chemokine (C—C motif) ligand 5; bone morphogenetic protein 4; calcyphosine; Uncharacterized protein LOC100131897; and CD74 molecule, major histocompatibility complex, class II invariant chain.

### Claim 18

A method for treating non-small cell lung carcinoma or cervical cancer, comprising screening a patient's carcinoma or cancer for the presence of LKB1 gene or protein loss or mutation, relative to wild type, and administering an effective amount of a TOR kinase inhibitor to the patient having non-small cell lung carcinoma or cervical cancer characterized by a gene expression level characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the gene expression level is obtained using gene mRNA measurement.

### Claim 20 (depends on 18)

The method of claim 18, wherein the gene expression level is obtained using RT-PCR or Affymetrix HGU133plus2.

### Claim 21 (depends on 18)

The method of claim 18, wherein the comparison of expression levels is performed using PAMR.

### Claim 22 (depends on 18)

The method of claim 18, wherein the gene expression level of the patient's carcinoma or cancer is characterized by upregulation of one or more of the following genes: scavenger receptor class A, member 5 (putative); fibrinogen gamma chain; fibrinogen alpha chain; insulin-like 4 (placenta); organic solute transporter beta; phosphodiesterase 1A, calmodulin-dependent; carbamoyl-phosphate synthetase 1, mitochondrial; frizzled homolog 10(Drosophila); mucin SAC, oligomeric mucus/gel-forming; trefoil factor 1; transient receptor potential cation channel, subfamily C, member 6; interleukin 1 receptor, type II; fibrinogen beta chain; chromosome 12 open reading frame 39; hypothetical gene supported by AK090616; R-spondin 3 homolog (Xenopus laevis); and interleukin 1 receptor, type II.

### Claim 23 (depends on 18)

The method of claim 18, wherein the gene expression level of the patient's carcinoma or cancer is characterized by downregulation of one or more of the following genes: chitinase 3-like 1 (cartilage glycoprotein-39); odz, odd Oz/ten-m homolog 2 (Drosophila); chemokine (C—C motif) ligand 5; bone morphogenetic protein 4; calcyphosine; Uncharacterized protein LOC100131897; and CD74 molecule, major histocompatibility complex, class II invariant chain.

### Claim 24

A method for treating Peutz-Jeghers Syndrome, comprising comparing a patient's gene expression level to wild type, and administering an effective amount of a TOR kinase inhibitor to the patient having Peutz-Jeghers Syndrome characterized by a gene expression level characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the gene expression level is obtained using gene mRNA measurement.

### Claim 26 (depends on 24)

The method of claim 24, wherein the gene expression level is obtained using RT-PCR or Affymetrix HGU133plus2.

### Claim 27 (depends on 24)

The method of claim 24, wherein the comparison of gene expression levels is performed using PAMR.

### Claim 28 (depends on 24)

The method of claim 24, wherein the patient's gene expression level is characterized by upregulation of one or more of the following genes: scavenger receptor class A, member 5 (putative); fibrinogen gamma chain; fibrinogen alpha chain; insulin-like 4 (placenta); organic solute transporter beta; phosphodiesterase 1A, calmodulin-dependent; carbamoyl-phosphate synthetase 1, mitochondrial; frizzled homolog 10 (Drosophila); mucin SAC, oligomeric mucus/gel-forming; trefoil factor 1; transient receptor potential cation channel, subfamily C, member 6; interleukin 1 receptor, type II; fibrinogen beta chain; chromosome 12 open reading frame 39; hypothetical gene supported by AK090616; R-spondin 3 homolog (Xenopus laevis); and interleukin 1 receptor, type II.

### Claim 29 (depends on 24)

The method of claim 24, wherein the patient's gene expression level is characterized by downregulation of one or more of the following genes: chitinase 3-like 1(cartilage glycoprotein-39); odz, odd Oz/ten-m homolog 2 (Drosophila); chemokine (C—C motif) ligand 5; bone morphogenetic protein 4; calcyphosine; Uncharacterized protein LOC 100131897; and CD74 molecule, major histocompatibility complex, class II invariant chain.

### Claim 30

A method of predicting response to treatment with a TOR kinase inhibitor in a patient having cancer, the method comprising:
a) obtaining a biological test sample from the patient's cancer;
b) obtaining the gene expression level of one or more genes selected from Table 1 in said biological test sample;
c) comparing said gene expression level to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation;
wherein the gene expression level of the biological test sample characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation, indicates an increased likelihood of response to TOR kinase inhibitor treatment of said patient's cancer.

### Claim 31 (depends on 30)

The method of claim 30, wherein the gene expression level of the biological test sample is obtained using gene mRNA measurement.

### Claim 32 (depends on 30)

The method of claim 30, wherein the gene expression level of the biological test sample is obtained using RT-PCR or Affymetrix HGU133plus2.

### Claim 33 (depends on 30)

The method of claim 30, wherein the comparison of gene expression levels is performed using PAMR.

### Claim 34

A kit comprising one or more containers filled with a TOR kinase inhibitor or a pharmaceutical composition thereof, reagents for measuring gene expression levels of a patient's cancer or of a patient having a tumor syndrome and instructions for measuring gene expression levels of a patient's cancer or of a patient having a tumor syndrome.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the measurement comprises measurement of the expression level one or more genes from Table 1.

### Claim 36 (depends on 34)

The kit of claim 34, wherein the gene expression measurement instructions are RT-PCT or Affymetrix HGU133plus2 instructions.

### Claim 37 (depends on 35)

The kit of claim 35, further comprising instructions for comparing the expression levels to a set of reference levels that represent the gene expression levels of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation.

### Claim 38 (depends on 37)

The kit of claim 37, wherein the instructions for the comparison of expression levels are instructions for using PAMR.
